Cargando…

Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect

PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated treatment effects vary by site of...

Descripción completa

Detalles Bibliográficos
Autores principales: Merlino, Dante J., Johnson, Jennifer M., Tuluc, Madalina, Gargano, Stacey, Stapp, Robert, Harshyne, Larry, Leiby, Benjamin E., Flanders, Adam, Zinner, Ralph, Axelrod, Rita, Curry, Joseph, Cognetti, David M., Mannion, Kyle, Kim, Young J., Rodeck, Ulrich, Argiris, Athanassios, Luginbuhl, Adam J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738605/
https://www.ncbi.nlm.nih.gov/pubmed/33344227
http://dx.doi.org/10.3389/fonc.2020.566315
_version_ 1783623153689296896
author Merlino, Dante J.
Johnson, Jennifer M.
Tuluc, Madalina
Gargano, Stacey
Stapp, Robert
Harshyne, Larry
Leiby, Benjamin E.
Flanders, Adam
Zinner, Ralph
Axelrod, Rita
Curry, Joseph
Cognetti, David M.
Mannion, Kyle
Kim, Young J.
Rodeck, Ulrich
Argiris, Athanassios
Luginbuhl, Adam J.
author_facet Merlino, Dante J.
Johnson, Jennifer M.
Tuluc, Madalina
Gargano, Stacey
Stapp, Robert
Harshyne, Larry
Leiby, Benjamin E.
Flanders, Adam
Zinner, Ralph
Axelrod, Rita
Curry, Joseph
Cognetti, David M.
Mannion, Kyle
Kim, Young J.
Rodeck, Ulrich
Argiris, Athanassios
Luginbuhl, Adam J.
author_sort Merlino, Dante J.
collection PubMed
description PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated treatment effects vary by site of involvement (primary tumor, lymph nodes) and determine how radiographic tumor shrinkage correlates with pathologic treatment effect. PATIENTS AND METHODS: Forty-four patients enrolled in trial NCT03238365 were treated with nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil, as determined by random assignment, followed by surgery on day 31. Radiographic volumetric response (RVR) was defined as percent change in tumor volume from pretreatment to posttreatment CT scan. Responders were defined as those with a 10% reduction in the volume of the primary tumor or lymph nodes (LN). Pathologic treatment effect (PTE) was defined as the area showing fibrosis or lymphohistiocytic inflammation divided by total tumor area. RESULTS: Sixteen of 32 patients (50%) with pathologic evidence of LN involvement exhibited discordant PTE between primary sites and LN. In four patients with widely discordant adjacent LN, increased PTE was associated with increased infiltration of tumor CD8(+) T cells and CD163(+) macrophages, whereas stromal regulatory T cells were associated with low nodal PTE. RVR correlated with PTE at both primary tumor (slope = 0.55, p < 0.001) and in LN (slope = 0.62, p < 0.05). 89% (16/18) of radiographic non-responders with T1–T3 primary sites had no (n = 7) or minimal PTE (n = 9), whereas 15/17 (88%) of radiographic responders had moderate (n = 12) or complete (n = 3) PTE. CONCLUSION: Nivolumab often induces discordant treatment effects between primary tumor sites and metastatic lymph nodes within subjects. This treatment discordance was also demonstrated in adjacent lymph nodes, which may correlate with local immune cell makeup. Finally, although these data were generated by a relatively small population size, our data support the use of early radiographic response to assess immunotherapy treatment effect in HNSCC.
format Online
Article
Text
id pubmed-7738605
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77386052020-12-17 Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect Merlino, Dante J. Johnson, Jennifer M. Tuluc, Madalina Gargano, Stacey Stapp, Robert Harshyne, Larry Leiby, Benjamin E. Flanders, Adam Zinner, Ralph Axelrod, Rita Curry, Joseph Cognetti, David M. Mannion, Kyle Kim, Young J. Rodeck, Ulrich Argiris, Athanassios Luginbuhl, Adam J. Front Oncol Oncology PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated treatment effects vary by site of involvement (primary tumor, lymph nodes) and determine how radiographic tumor shrinkage correlates with pathologic treatment effect. PATIENTS AND METHODS: Forty-four patients enrolled in trial NCT03238365 were treated with nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil, as determined by random assignment, followed by surgery on day 31. Radiographic volumetric response (RVR) was defined as percent change in tumor volume from pretreatment to posttreatment CT scan. Responders were defined as those with a 10% reduction in the volume of the primary tumor or lymph nodes (LN). Pathologic treatment effect (PTE) was defined as the area showing fibrosis or lymphohistiocytic inflammation divided by total tumor area. RESULTS: Sixteen of 32 patients (50%) with pathologic evidence of LN involvement exhibited discordant PTE between primary sites and LN. In four patients with widely discordant adjacent LN, increased PTE was associated with increased infiltration of tumor CD8(+) T cells and CD163(+) macrophages, whereas stromal regulatory T cells were associated with low nodal PTE. RVR correlated with PTE at both primary tumor (slope = 0.55, p < 0.001) and in LN (slope = 0.62, p < 0.05). 89% (16/18) of radiographic non-responders with T1–T3 primary sites had no (n = 7) or minimal PTE (n = 9), whereas 15/17 (88%) of radiographic responders had moderate (n = 12) or complete (n = 3) PTE. CONCLUSION: Nivolumab often induces discordant treatment effects between primary tumor sites and metastatic lymph nodes within subjects. This treatment discordance was also demonstrated in adjacent lymph nodes, which may correlate with local immune cell makeup. Finally, although these data were generated by a relatively small population size, our data support the use of early radiographic response to assess immunotherapy treatment effect in HNSCC. Frontiers Media S.A. 2020-12-02 /pmc/articles/PMC7738605/ /pubmed/33344227 http://dx.doi.org/10.3389/fonc.2020.566315 Text en Copyright © 2020 Merlino, Johnson, Tuluc, Gargano, Stapp, Harshyne, Leiby, Flanders, Zinner, Axelrod, Curry, Cognetti, Mannion, Kim, Rodeck, Argiris and Luginbuhl http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Merlino, Dante J.
Johnson, Jennifer M.
Tuluc, Madalina
Gargano, Stacey
Stapp, Robert
Harshyne, Larry
Leiby, Benjamin E.
Flanders, Adam
Zinner, Ralph
Axelrod, Rita
Curry, Joseph
Cognetti, David M.
Mannion, Kyle
Kim, Young J.
Rodeck, Ulrich
Argiris, Athanassios
Luginbuhl, Adam J.
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
title Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
title_full Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
title_fullStr Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
title_full_unstemmed Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
title_short Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
title_sort discordant responses between primary head and neck tumors and nodal metastases treated with neoadjuvant nivolumab: correlation of radiographic and pathologic treatment effect
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738605/
https://www.ncbi.nlm.nih.gov/pubmed/33344227
http://dx.doi.org/10.3389/fonc.2020.566315
work_keys_str_mv AT merlinodantej discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT johnsonjenniferm discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT tulucmadalina discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT garganostacey discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT stapprobert discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT harshynelarry discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT leibybenjamine discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT flandersadam discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT zinnerralph discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT axelrodrita discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT curryjoseph discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT cognettidavidm discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT mannionkyle discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT kimyoungj discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT rodeckulrich discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT argirisathanassios discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect
AT luginbuhladamj discordantresponsesbetweenprimaryheadandnecktumorsandnodalmetastasestreatedwithneoadjuvantnivolumabcorrelationofradiographicandpathologictreatmenteffect